Advertising Industry Newswire

Search

// archives

Eularis

This tag is associated with 4 posts

Pharmaco Marketing: Eularis Reports Help Do More for Real Growth

By Carly Zed Zander ⋅ April 13, 2010 ⋅ Post a comment

LONDON, U.K. /Advertising Industry Newswire/ — The pharmaceutical industry is facing unprecedented challenges on many fronts – a slew of patient expiries, a lack of blockbusters in the pipeline to replace the patent expiries, decreasing growth in many major markets, generic competition, constantly changing regulatory and competitive environment rendering old tools for analysis obsolete, increased [...]

New report from Eularis: Pharmaceutical eMarketing using Social Media – How to Use It Effectively

By Carly Zed Zander ⋅ September 8, 2009 ⋅ Post a comment

NEW YORK, N.Y. and LONDON, U.K. /Advertising Industry Newswire/ — Eularis is announcing the release of its report “How To Harness The Power Of Social Media In Pharmaceutical eMarketing.” This report puts to rest the issues around “can’t,” and shows Pharmaceutical marketers how they can utilize social media networks effectively to meet their marketing objectives. [...]

Eularis to Hold Pharmaceutical Marketing ROI MasterClass in London

By Carly Zed Zander ⋅ May 18, 2009 ⋅ Post a comment

LONDON, U.K. — Dr. Andree Bates, President of the Pharmaceutical analytics company Eularis, will be delivering a MasterClass on how to tell if you are making the wrong marketing decision. The Pharmaceutical Industry is under significant pressure to consider its costs very carefully. Since marketing budgets often represent a major portion of a company’s cost [...]

Branded Pharmaceutical Companies Can Expect to See Sales Drops of up to 70 Percent After Patent Expiration from Generic Competition

By Carly Zed Zander ⋅ July 14, 2008 ⋅ Post a comment

NEW YORK, N.Y. and TOKYO, JAPAN — Branded Pharmaceutical companies are painfully aware of the astronomical growth of Generics competition. By the end of this year, Branded drug patents accounting for sales of more than $80 Billion will expire, resulting in major losses in company profits. In the United States, the Generics Industry claims more [...]